Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study

NCT05018182 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT05018182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05018182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Observe the Pathological Remission Rate and Safety of FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer With a Single-arm, Open, Prospective Phase II Exploratory Clinical Study
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 2, 2021
Completion date
August 2, 2022
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

folfoxiri regimen, high-risk locally advanced colorectal cancer, neoadjuvant chemotherapy